Section 5 of 6
Economic information and modeling report
1 evidence topic · 1 source
Modeling overview
Summary
The report contains a Japanese receipt-score-based estimate of 0.91 million JPY per month for tirabrutinib treatment. This is a treatment-cost estimate, not a United States average sales price, wholesale acquisition cost, or estimate of the change in a payer's total budget following tirabrutinib adoption.
No tirabrutinib-specific budget impact model was identified in the evidence assembled for this report. The available treatment-cost evidence does not establish population-level budget impact, offsets from avoided healthcare utilization, or cost-effectiveness.
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.